Premium
Detection of minimal residual disease in acute lymphoblastic leukemia by flow cytometry with monoclonal antibodies
Author(s) -
Imamura Nobutaka,
Kuramoto Atsushi
Publication year - 1991
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.2830380416
Subject(s) - calla , minimal residual disease , terminal deoxynucleotidyl transferase , monoclonal antibody , flow cytometry , cd20 , medicine , immunophenotyping , antigen , leukemia , monoclonal , cd19 , antibody , acute lymphocytic leukemia , immunology , pathology , immunohistochemistry , lymphoblastic leukemia , tunel assay
To detect more precisely the minimal residual disease in acute lymphoblastic leukemia (ALL), two‐color flow cytometric analysis for the detection of cell‐surface antigen (CD10; CALLA) and nuclear terminal deoxynucleotidyl transferase (TdT) was performed in the six patients with CALLA‐positive ALL coexpressing TdT. In all patients, the leukemic blasts coexpressed la (HLA‐DR), CD9, CD19, CD20, CD24, and CD10. Five of six patients achieved complete remission, but one has so far relapsed. No leukemic blasts (CD10 + , TdT + ) were detected at the time of complete remission. During maintenance chemotherapy, leukemic blasts coexpressed C10 and TdT were found 2.32% in the patient's peripheral blood by two‐color analysis, whereas no obvious leukemic cells were recognized morphologically. The patient relapsed leukemia with the same phenotype 4 weeks after the examination. On the basis of our findings, we suggest that two‐color flow cytometric analysis with the use of these antibodies is quite valuable to detect the minimal residual leukemic cells in a patient with ALL. The reduction of leukemic cells below the threshold of detection of methods currently available appears to be necessary to achieve a cure in ALL. Hence accurate diagnosis of ALLs with monoclonal antibodies (MAbs) should contribute substantially to the development of an effective form of therapy for their cure.